Previous 10 | Next 10 |
CAMBRIDGE, Mass., May 29, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that the Company will participate in an u...
CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a virtual analyst/investor event and conferenc...
Continued high rate of SVR35 in 1L patients: 72% at 12 weeks and 67% at 24 weeks SVR35 responses and transfusion dependence conversion observed in 2L monotherapy patients Improvement in bone marrow fibrosis seen across treatment arms Additional data to be presented at EHA fro...
Constellation Pharmaceuticals, Inc. (CNST) Q1 2020 Earnings Conference Call May 6, 2020 8:00 AM ET Company Participants Kia Khaleghpour - Vice President, Investor Relations and Communications Jigar Raythatha - President and Chief Executive Officer Emma Reeve - Chief Financial Off...
Image source: The Motley Fool. Constellation Pharmaceuticals (NASDAQ: CNST) Q1 2020 Earnings Call May 6, 2020 , 8:00 a.m. ET Operator Continue reading
The following slide deck was published by Constellation Pharmaceuticals, Inc. in conjunction with their 2020 Q1 earnings Read more ...
EHA abstracts to publish on May 14 with an interim update across the MANIFEST trial cohorts Constellation to provide an additional interim update from MANIFEST at EHA in mid-June Company continues to effectively make progress on its milestones in the face of the COVID-19 pandemic ...
CAMBRIDGE, Mass., April 28, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, will host a conference call at 8:00 AM EDT on May 6, 2020, to discuss its ...
Amid widespread uncertainty in healthcare around COVID-19 impact, Baird is focusing on clinical catalysts that continue to power biotech picks - and in particular it's declaring fresh picks on two stocks with data forthcoming. More news on: Constellation Pharmaceuticals, Inc., Blueprint Me...
CAMBRIDGE, Mass., April 06, 2020 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics, today announced that Richard Levy, M.D., has been appoi...
News, Short Squeeze, Breakout and More Instantly...
Constellation Pharmaceuticals Inc. Company Name:
CNST Stock Symbol:
NASDAQ Market:
Constellation Pharmaceuticals Inc. Website:
Company Announces Successful Completion of Tender Offer Moves Forward with Strategic Funding Partnership with Royalty Pharma PLANEGG / MUNICH, GERMANY / ACCESSWIRE / July 15, 2021 / MorphoSys AG (FSE:MOR; NASDAQ:MOR) ("MorphoSys") today announced the successful completion of its...
MUNICH, GERMANY and WILMINGTON, DE / ACCESSWIRE / July 1, 2021 / MorphoSys AG (FSE:MOR) (NASDAQ:MOR) ("MorphoSys") today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), for its tender offer for Constellation P...
Translational data support the disease-modifying potential of pelabresib Central pathology review confirmed bone marrow fibrosis improvements observed with pelabresib treatment Impact of pelabresib treatment observed across a wide range of myelofibrosis patient subgroups...